Speaker Profile

Ph.D., CEO & Co-Founder, Precision NanoSystems

James is the CEO and co-founder of Precision NanoSystems, Inc. (PNI), a commercial-stage life science company at the convergence of gene therapy, nanotechnology, and advanced therapeutics. PNI provides comprehensive solutions for the development and manufacture of nanoparticle based Precision and Gene Therapies. This includes in the areas of RNA, DNA, CRISPR, small molecule, and protein therapeutics for the treatment of cancer, infectious disease, rare disease, cardiometabolic disease, and others. James earned a B.A.Sc. in engineering physics from UBC and a Ph.D. in genetics from the Institute for Systems Biology in Seattle, WA. James worked at the Seattle based Venture Capital firm, the Accelerator Corporation concurrent with his Ph.D. and has extensive experience in the science and commercialization of microfluidics, nanotechnology, and systems biology. James is a Director of Life Science British Columbia and an active participant of the bio-entrepreneurial community.

Clinical and Research Tools Showcase:
Precision NanoSystems

Precision NanoSystems (PNI) is a leading technology provider to drug developers for the discovery and manufacture of gene therapies and advanced therapeutics. PNI’s core technology includes its NanoAssemblr microfluidic-based continuous flow platform for nanomedicine development and manufacture, and its GenVoy nanoparticle delivery technology for nucleic acid delivery. PNI provides its technology to over 200 leading pharmaceutical companies, biotechnology companies, and academic institutions in over 20 countries worldwide.

 Session Abstract – PMWC 2020 Silicon Valley

The PMWC 2020 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.